Delamanid: A new armor in combating drug-resistant tuberculosis

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 3, 2014, Pages 222-224

  Xavier, Alphienes Stanley ^a   Lakshmanan, Mageshwaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Delamanid; multidrug resistant tuberculosis; mycolic acid inhibitor

Indexed keywords

DELAMANID; RIFAMPICIN;

ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SOLUBILITY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; QT PROLONGATION; SPUTUM CULTURE; TREATMENT DURATION;

EID: 84905712035     PISSN: 0976500X     EISSN: 09765018     Source Type: Journal    
DOI: 10.4103/0976-500X.136121     Document Type: Article

References (7)

1. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54:579-81.
2. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011;15:949-54.
3. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466.
4. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
5. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013;41:1393-400.
6. International AIDS Society. Available from: http://www.iasociety.org/ Abstracts/A200747433.aspx. [Last accessed on 2014 Jan 16].
7. European Medicines Agency-Human medicines-Deltyba. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002552/WC500155458.pdf. [Last accessed on 2014 Jan 16].